Growth+Onco also connects subscribers to cancer experts across the world to discuss key topics of relevance. Our clients speak with researchers, market experts and market access professionals across the world as part of their subscriptions.

Growth+Onco also enables subscribers to custom insights based upon their requirements. GRG’s analyst team also work with clients on adding extra insights depending upon the type of their subscription.

The significance of this report not only lies for the clients having a steady presence in the tumor space but also for the clients which are yet to make a mark in the tumor space with a clear vision and strategy in place.

The insights in the report will feed-into the key decision- making the process and enable the development of a futuristic strategy/projects.

Thus, the report is helpful –

Disease Landscape & Epidemiology

• Disease overview including risk factors, diagnosis, symptoms, pathophysiology & staging or classification
• Assess unmet needs & corresponding opportunities
• Epidemiology includes incidence, prevalence, mortality, yearly rates of incidence/ prevalence (1,2 or 5-years) and 5-yr survival rate of the respective tumor in US, EU5, China and Japan. (May include other countries, based on the client requirement)

Current Treatment Landscape

• Current treatment algorithm
• Current treatment benchmarks
• Biomarker segmentation and corresponding approval
• Approved treatment distribution as per the line of therapy
• Launches of approved therapies
• Patent expires of approved therapies

Emerging Treatment Landscape and Competition Landscape

• Emerging MoAs and Biomarker-driven Segments
• Emerging Treatment Algorithm
• Potential Gamechangers & their Estimated Launch Timeline
• Clinical Hurdles and Entry Barriers
• Required Efficacy Thresholds and Endpoints
• Strategy based recommendation on differential potential of emerging candidate

Clinical Trial Analysis

• Trial profiles of key Competitors including the following information
• Trial details including patient population, Biomarker segmentation (if any), Trial design, Start date, end date
• Treatment details including arms, Primary and secondary end points, Dose and dosage form,
• Results – efficacy and safety results
• List of Trial failures

• Acquire not only the basic and essential information about the tumor, but also a detailed description around many fundamental data elements like key gamechangers, emerging treatment landscape etc. that will aid in planning key clinical and commercial developments and BD&L decisions.
• Stay updated with all the prevailing dynamics of the tumor world.
• Obtain comprehensive form of all the information collected through in-depth research and the insights drawn from data analysis of the facts and figures gathered through secondary and primary market research (enriched with expert insights around the globe* yielding the overview of global perspective).
• Procure all the data in one consolidated report and avoid referring to the multiple sources and citations

• The significance of this report not only lies for the clients having a steady presence in the tumor space but also for the clients which are yet to make a mark in the tumor space with a clear vision and strategy in place.
• The insights in the report will feed-into the key decision- making process and enable the development of a futuristic strategy/projects.
• Thus, the report is helpful

  1. 1. To stay updated with all the recent developments in the tumor space

     2. To design diseases area strategy to assess any business development opportunities

     3. To design the asset profile, which will ultimately support in building strong oncology pipeline

     4. To support product development via strategy-based recommendation on differential potential of emerging candidate

     5. To train internal resources, as this is a knowledge book which will be like a mini encyclopedia for the tumor space